Best Pharma Stocks for August 2026 Based on 5‑Year CAGR: Neuland Laboratories, Strides Pharma and More

The pharmaceutical sector remains an important part of India's healthcare and export ecosystem, supported by demand for medicines, APIs, specialty therapies and contract manufacturing services. Companies in this sector benefit from research capabilities, global regulatory approvals, expanding therapeutic portfolios and rising healthcare spending.

These factors can support long-term growth and influence companies' financial performance over time. Based on available data for August 2026, the following pharma stocks stand out based on their 5-year CAGR performance.

Best Pharma Stocks Based on 5‑Year CAGR

Note: Data as on August 7, 2026

Neuland Laboratories

Neuland Laboratories is a specialised pharmaceutical company focused on active pharmaceutical ingredients and CDMO services. The company operates as a dedicated API manufacturer, offering both high-volume and specialty APIs across multiple therapeutic segments.

It also provides end-to-end services covering drug development, process development, scale-up, and commercial manufacturing. Its growth is supported by rising demand for outsourced pharmaceutical manufacturing and complex API solutions.

Strides Pharma Science

Strides Pharma Science develops and manufactures pharmaceutical products for global markets. The company's portfolio includes essential generics and specialty formulations across various therapeutic segments.

It operates manufacturing facilities across India that support its international supply chain. Business performance is driven by demand for affordable medicines, differentiated formulations, and expansion across overseas markets.

Laurus Labs

Laurus Labs is a research-driven pharmaceutical manufacturer with operations spanning APIs, intermediates, formulations, and specialised pharmaceutical products. The company has built expertise in therapeutic areas including antiretroviral, oncology, cardiovascular, and gastro treatments.

It has expanded across the pharmaceutical value chain while strengthening its manufacturing and research capabilities. Growth is influenced by API demand, healthcare spending, and technology-led product development.

Caplin Point Laboratories

Caplin Point Laboratories develops and manufactures formulations, injectables, ophthalmic products, and other pharmaceutical dosage forms. Through its Caplin Steriles business, the company has strengthened its position in the injectable products market.

It has secured approvals for products across regulated international markets, including the United States. Business growth is supported by product diversification, manufacturing expansion, and global healthcare demand.

Ajanta Pharma

Ajanta Pharma is a specialty pharmaceutical company with operations across India, emerging markets, and the United States. The company focuses on branded generics and generic medicines across therapeutic areas such as cardiology, ophthalmology, dermatology, and pain management.

Its business model emphasises differentiated products backed by research and development capabilities. Growth is supported by new product launches and expansion across domestic and international markets.

AstraZeneca Pharma India

AstraZeneca Pharma India operates in prescription medicines across key therapy areas including oncology, cardiovascular, renal, respiratory, and rare diseases. The company benefits from access to innovative medicines developed by its global parent.

It continues to introduce new therapies in India following regulatory approvals and increasing healthcare requirements. Business performance is linked to specialty medicine adoption and demand for advanced treatment options.

Lupin

Lupin is a diversified pharmaceutical company with operations spanning generics, complex formulations, branded products, and specialty medicines. The company maintains a strong presence in global markets, particularly in the generics segment.

It also supports formulation operations through its API manufacturing capabilities. Growth is supported by affordable healthcare demand, complex generics, and continued manufacturing expansion.

Alivus Life Sciences

Alivus Life Sciences, formerly known as Glenmark Life Sciences, focuses on the development and manufacture of specialised active pharmaceutical ingredients. The company serves pharmaceutical customers globally with a portfolio concentrated on high-value and non-commoditised APIs.

Its operations are supported by technology-driven manufacturing and research capabilities. Business growth depends on demand for differentiated pharmaceutical ingredients and chronic therapy products.

Zydus Lifesciences

Zydus Lifesciences is an integrated healthcare company operating across formulations, APIs, biologics, vaccines, animal health, consumer wellness, and medical devices. The company serves multiple therapeutic segments, including cardiology, oncology, pain management, anti-infectives, and neurosciences.

Its manufacturing network supports a wide range of dosage forms and healthcare products. Growth is supported by innovation, biosimilars, vaccines, and expanding healthcare demand.

GlaxoSmithKline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals is the Indian pharmaceutical arm of global biopharmaceutical company GSK. Its portfolio includes vaccines, anti-infectives, respiratory medicines, dermatology products, pain management therapies, and specialty medicines.

The company benefits from a strong global research ecosystem and established brands in the domestic market. Business performance is influenced by innovative medicines, vaccine demand, and healthcare market expansion.

Track the stock market trends in Hindi. Visit Angel One News for the latest market trends, insights, and share market news in Hindi.

Conclusion

The pharma stocks featured in this list represent a mix of API manufacturers, specialty drug developers, CDMO providers, and diversified pharmaceutical companies. Their long-term performance reflects growth in exports, healthcare demand, innovation, and manufacturing capabilities.

Return ratios and valuations vary across companies depending on their business models and stage of growth. As of August 2026, these stocks highlight some of the top-performing pharmaceutical companies based on 5‑year CAGR.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.